Fulcrum Therapeutics (FULC) Assets (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Assets data on file, last reported at $346.8 million in Q1 2026.

• Assets for Q1 2026 came in at $346.8 million, up 42.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $346.8 million (up 42.91% YoY), and the FY2025 annual result was $366.3 million, up 40.49% from the prior year.
• Assets eased to $346.8 million in Q1 2026 per FULC's latest filing, from $366.3 million in the prior quarter.
• Over five years, Assets peaked at $366.3 million in Q4 2025 and troughed at $195.2 million in Q2 2022.
• A 5-year average of $265.5 million and a median of $257.7 million in 2023 frame the typical range for Assets.
• The sharpest annual moves came in 2023 and 2024: Assets soared 53.83% in 2023, then fell 27.57% in 2024.
• A 5-year view of Assets shows it stood at $226.7 million in 2022, then climbed by 13.68% to $257.7 million in 2023, then gained by 1.17% to $260.7 million in 2024, then soared by 40.49% to $366.3 million in 2025, then retreated by 5.33% to $346.8 million in 2026.
• Business Quant data shows FULC's Assets at $346.8 million in Q1 2026, $366.3 million in Q4 2025, and $214.9 million in Q3 2025.